Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer

Prostate

Volumn 75, Issue 15, 2015, Pages 1814-1820

  Maughan, Benjamin L ^a   Xhou, Xian C ^a   Suzman, Daniel L ^a   Nadal, Rosa ^a   Bassi, Sunakshi ^a   Schweizer, Michael T ^b   Antonarakis, Emmanuel S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

abiraterone; castration resistant prostate cancer; docetaxel; sequencing

Indexed keywords

ABIRATERONE; DOCETAXEL; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG DOSE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84942832956     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23064     Document Type: Article

References (19)

1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512.
2. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS,. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. NEJM 2015; DOI: 10.1056/NEJMoa1503747.
3. James ND, Sydes MR, Mason MD, Clarke NW, Dearnaley DP, Spears MR, Millman R, Parker C, Ritchie AWS, Russell JM, Staffurth J, Jones RJ, Tolan SP, Wagstaff J, Protheroe A, Srinivasan R, Birtle AJ, O'Sullivan JM, Cathomas R, Parmar MMK, STAMPEDE Investigators. Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33, (suppl; abstr 5001).
4. Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES,. Clinical activity of enzalutamide in docetaxel-naive and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 2014; 74 (15): 1560-1568.
5. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV,. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65 (1): 30-36.
6. Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM,. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014; 120 (7): 968-975.
7. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J,. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371 (11): 1028-1038.
8. Maughan BL, Antonarakis ES,. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother 2015; 16 (10): 1521-1537.
9. Hay CW, McEwan IJ,. The impact of point mutations in the human androgen receptor: Classification of mutations on the basis of transcriptional activity. PLoS One. 2012; 7 (3): e32514.
10. Coffey K, Robson CN,. Regulation of the androgen receptor by post-translational modifications. J Endocrinol 2012; 215 (2): 221-237.
11. Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G,. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015; 16 (6): e279-e292.
12. Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN,. A retrospective, canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate. 2014; 74 (15): 1544-1550.
13. Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Mulick Cassidy A, Olmos D, Attard G, de Bono J,. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: Clinical evidence for cross-resistance? Ann Oncol 2012; 23 (11): 2943-2947.
14. Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES,. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol 2014; 66 (4): 646-652.
15. Zafeiriou Z, Ferraldeschi R, Omlin AG, Pezaro C, Mukherji D, Lorente D, Altavilla A, Sideris S, Rescigno P, Mateo J, Bianchini D, Smith A, Lopez RP, Mehra N, Ravi P, Grist E, Tunariu N, Attard G, De Bono JS,. Sequencing of docetaxel (D) and abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO 2014; 25:(suppl 4 abstract 791P).
16. Schweizer MT, Huang P, Kattan MW, Kibel AS, de Wit R, Sternberg CN, Epstein JI, Eisenberger MA,. Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): Important lessons for future trials. Cancer 2013; 119 (20): 3610-3618.
17. Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S,. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): A phase 3 randomised controlled trial. Lancet Oncol 2015; 16 (7): 787-794.
18. Sandler HM, Hu C, Rosenthal SA, Sartor O, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto M, Pervez M, Balogh AG, Rodrigues G, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz ER, Raben A, Paulus R, Shipley WU,. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol 2015; 33, (suppl; abstr LBA5002).
19. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J,. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA 2015; doi: 10.1001/jamaoncol.2015.1341. [Epub ahead of print].